Tag Archives: NASDAQ:ORTX

Orchard Therapeutics (ORTX) Gets a Buy Rating from Oppenheimer

Oppenheimer analyst Esther Rajavelu maintained a Buy rating on Orchard Therapeutics (ORTX – Research Report) yesterday and set a price target of $26.00. The company’s shares closed last Thursday at $10.28. According to TipRanks.com, Rajavelu is a 1-star analyst with

Analysts Have Conflicting Sentiments on These Healthcare Companies: Orchard Therapeutics (NASDAQ: ORTX) and Epizyme (NASDAQ: EPZM)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Orchard Therapeutics (ORTX – Research Report) and Epizyme (EPZM – Research Report). Orchard Therapeutics (ORTX) In a report released today, Esther Rajavelu from

Cowen & Co. Keeps Their Buy Rating on Orchard Therapeutics (ORTX)

Cowen & Co. analyst Yaron Werber maintained a Buy rating on Orchard Therapeutics (ORTX – Research Report) today and set a price target of $28.00. The company’s shares closed last Monday at $11.39. According to TipRanks.com, Werber is a 5-star

Analysts Offer Insights on Healthcare Companies: Orchard Therapeutics (NASDAQ: ORTX) and Arbutus Biopharma (NASDAQ: ABUS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Orchard Therapeutics (ORTX – Research Report) and Arbutus Biopharma (ABUS – Research Report). Orchard Therapeutics (ORTX) Cowen & Co. analyst Yaron Werber maintained a Buy

Orchard Therapeutics PLC (ORTX) Initiated with a Buy at Cowen & Co.

In a report issued on September 13, Yaron Werber from Cowen & Co. initiated coverage with a Buy rating on Orchard Therapeutics PLC (ORTX – Research Report) and a price target of $27. The company’s shares closed last Monday at

Orchard Therapeutics PLC (ORTX) Gets a Buy Rating from Cowen & Co.

In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Orchard Therapeutics PLC (ORTX – Research Report), with a price target of $27. The company’s shares closed last Monday at $14.70. According to TipRanks.com,